BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6844679)

  • 1. [Effect of D-L carnitine on the metabolism of plasma lipids, copper and zinc in hemodialysis].
    Bustamante J; Martín Mateo MC; Bustamante R; San Segundo D
    Rev Clin Esp; 1983 Jan; 168(1):41-3. PubMed ID: 6844679
    [No Abstract]   [Full Text] [Related]  

  • 2. Zinc and copper concentration in plasma and erythrocytes of patients with chronic renal failure.
    Paniagua-Sierra JR; Pérez-López A; Diaz-Bensussen S; Solís-Alpuche L; Saavedra-Guatemala H; Exaire-Murad JE
    Arch Invest Med (Mex); 1981; 12(1):69-82. PubMed ID: 7247613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The trace elements zinc and copper in chronic renal failure].
    Prehn B
    Z Urol Nephrol; 1988 Jan; 81(1):35-42. PubMed ID: 3364046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Effect of L-carnitine supplementation on lipid metabolism of renal failure, dialysis-dependent children and adolescents].
    Böhles H; Michalk D; von Wendt-Göknur E
    Infusionstherapie; 1991 Oct; 18(5):224-6. PubMed ID: 1769735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Effect of chronic hemodialysis on the copper and zinc trace element content in the blood in chronic renal insufficiency].
    Golod EA; Chudnovskaia MV; Makhlin NV
    Urol Nefrol (Mosk); 1976; (6):50-3. PubMed ID: 1006882
    [No Abstract]   [Full Text] [Related]  

  • 6. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency.
    Zumkley H; Bertram HP; Lison A; Knoll O; Losse H
    Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Plasma and intra-erythrocytic concentrations of copper and zinc in uremic patients treated by periodic hemodialysis].
    Agenet C; Brugère CC; Reynier JP
    Ann Biol Clin (Paris); 1989; 47(8):493-6. PubMed ID: 2690680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Trace element changes in the serum of dialysis patients].
    Cullmann W; Vlaho M
    Fortschr Med; 1981 Mar; 99(12):413-4. PubMed ID: 7227937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Lipid metabolism and lipid utilization in renal failure].
    Druml W; Laggner A; Lenz K; Balcke P; Kleinberger G; Schmidt P
    Infusionsther Klin Ernahr; 1983 Aug; 10(4):206-12. PubMed ID: 6618660
    [No Abstract]   [Full Text] [Related]  

  • 10. Estimation of intake of zinc, copper and iron in the diet of patients with chronic renal failure treated by haemodialysis.
    Szpanowska-Wohn A; Kolarzyk E; Chowaniec E
    Biol Trace Elem Res; 2008 Aug; 124(2):97-102. PubMed ID: 18446276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Copper metabolism in uremia: effect of dialysis and zinc supplementation.
    Mahajan SK; Rye D; Sondheimer JH; McDonald FD
    Trans Am Soc Artif Intern Organs; 1985; 31():521-5. PubMed ID: 3837501
    [No Abstract]   [Full Text] [Related]  

  • 12. [Results of a multicenter study on the effect on serum triglycerides and cholesterol administration of carnitine in chronic uremia patients undergoing periodic hemodialysis treatment].
    Toigo G; Situlin R; Dardi F; Bazzato G; Vasile A; Tesio F; Ciman M; Guarnieri GF
    G Clin Med; 1982; 63(11-12):841-9. PubMed ID: 7182204
    [No Abstract]   [Full Text] [Related]  

  • 13. [Copper, cerulopasmin and zinc in relation to the metabolism of lipids in arteriosclerotic patients].
    Bustamante Bustamante J; Martín Mateo MC; Fernández B de Quirós J
    Rev Clin Esp; 1975 Nov; 139(3):243-6. PubMed ID: 1197847
    [No Abstract]   [Full Text] [Related]  

  • 14. [Disorders of lipid metabolism in children with chronic kidney insufficiency].
    Peco-Antić A; Popović-Rolović M; Vitić J; Nikolić V; Calić-Perisić N; Mancić M; Popović D; Erdeljan N; Jovanović O
    Srp Arh Celok Lek; 1984; 112(7-8):747-60. PubMed ID: 6523260
    [No Abstract]   [Full Text] [Related]  

  • 15. Longitudinal study of serum zinc and copper levels in hemodialysis patients and their relation to biochemical markers.
    Navarro-Alarcon M; Reyes-Pérez A; Lopez-Garcia H; Palomares-Bayo M; Olalla-Herrera M; Lopez-Martinez MC
    Biol Trace Elem Res; 2006 Dec; 113(3):209-22. PubMed ID: 17194922
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis.
    Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL
    Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total carnitine and acylated carnitine ratio: relationship of free carnitine with lipid parameters in pediatric dialysis patients.
    Marín VB; Azocar M; Molina M; Guerrero JL; Ratner R; Cano F
    Adv Perit Dial; 2006; 22():130-5. PubMed ID: 16983956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of L-carnitine on insulin resistance in hemodialysed patients with chronic renal failure.
    Günal AI; Celiker H; Dönder E; Günal SY
    J Nephrol; 1999; 12(1):38-40. PubMed ID: 10203002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zinc transfer during hemodialysis.
    Hosokawa S; Kohira S; Tomoyoshi T; Nonaka M; Nishio T; Sawanishi K
    Life Support Syst; 1983; 1 Suppl 1():133-6. PubMed ID: 6336393
    [No Abstract]   [Full Text] [Related]  

  • 20. [Zinc in patients with chronic renal insufficiency subjected to periodic maintenance hemodialysis].
    Temes-Montes XL; Picaporte MA; Herrero E; Otero A; Sánchez-Guisande D; Sánchez-Sicilia L
    Rev Clin Esp; 1982 May; 165(3):189-91. PubMed ID: 7134531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.